A modified Phase I trial of radiation dose escalation in 3D conformal radiation therapy with concurrent vinorelbine and carboplatin chemotherapy for non-small-cell lung cancer

Journal of Radiation Research

Volumn 54, Issue 1, 2013, Pages 126-134

  Lin, Qiang ^a   Liu, Yue'e ^a   Wang, Na ^a   Huang, Yuehua ^a   Ge, Xiaohui ^b   Ren, Xiaocang ^a   Chen, Xueji ^a   Hu, Jing ^a   Guo, Zhijun ^a   Zhao, Yannan ^a   Asaumi, Junichi ^c  

^a HEBEI MEDICAL UNIVERSITY   (China)

^b HEBEI UNIVERSITY   (China)

^c OKAYAMA UNIVERSITY   (Japan)

Author keywords

3D conformal radiation therapy; concurrent chemoradiotherapy; dose escalation; non small cell lung cancer

Indexed keywords

BIOLOGICAL ORGANS; CHEMORADIOTHERAPY; CHEMOTHERAPY; DISEASES; RADIATION; TOXICITY;

3D CONFORMAL RADIATION THERAPY; CARBOPLATIN; CONCURRENT CHEMORADIOTHERAPY; CONCURRENT CHEMOTHERAPY; DOSE ESCALATION; DOSE LIMITING TOXICITY; NON SMALL CELL LUNG CANCER; PHASE I; RESPONSE RATE; VINORELBINE;

RADIOTHERAPY;

EID: 84872046445     PISSN: 04493060     EISSN: 13499157     Source Type: Journal    
DOI: 10.1093/jrr/rrs081     Document Type: Article

References (24)

1. Parkin D-M, Bray F, Ferlay J et al. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.
2. Perez C-A, Pajak T-F, Rubin P et al. Long-term observations of the patterns of failure in patients with unresectable non-oat cell carcinoma of the lung treated with definitive radiotherapy. Report by the Radiation Therapy Oncology Group. Cancer 1987;59:1874-81.
3. Dillman R-O, Herndon J, Seagren S-L et al. Improved survival in stage III non-small-cell lung cancer: Seven year follow-up of cancer and leukemia group B (CALGB) 8433 trial. J Natl Cancer Inst 1996;88:1210-5.
4. Furuse K, Fukuoka M, Kawahara M et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small cell lung cancer. J Clin Oncol 1999;17:2692-9.
5. Liang H-Y, Zhou H, Li X-L et al. Chemo-radiotherapy for advanced non-small cell lung cancer: Concurrent or sequential? It's no longer the question: A systematic review. Int J Cancer 2010;127:718-28.
6. Lichter AS, Lawrence TS. Recent advances in radiation oncology. N Engl J Med 1995;332:371-9.
7. Bradley J-D, Moughan J, Graham M-V et al. A phase I/II radiation dose escalation study with concurrent chemotherapy for patients with inoperable stages I to III non-small-cell lung cancer: Phase I results of RTOG 0117. Int J Radiat Oncol Biol Phys 2010;77:367-72.
8. Vokes E-E, Herndon J-E, II, Crawford J et al. Randomized phase II study of cisplatin with gemcitabine or paclitaxel or vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy for stage IIIB non-small-cell lung cancer: Cancer and leukemia group B study 9431. J Clin Oncol 2002;20:4191-8.
9. Wu K-L, Chen G-Y, Xu Z-Y et al. Three-dimensional conformal radiation therapy for squamous cell carcinoma of the esophagus: A prospective phase I/II study. Radiother Oncol 2009;93:454-7.
10. Lin Q, Gao X-S, Qiao X-Y et al. Phase I trial of escalatingdose cisplatin with 5-fluorouracil and concurrent radiotherapy in Chinese patients with esophageal cancer. Acta Med Okayama 2008;62:37-44.
11. Zhu G-Y, Xia T-Y, Wang L-H et al. Consensus and controversies on delineation of radiotherapy target volume for patients with non-small cell lung cancer. Chin J Radiat Oncol 2008;17:432-6 (in Chinese).
12. Wang J, Qiao X-Y, Lu F-H et al. TGF-beta1 in serum and induced sputum for predicting radiation pneumonitis in patients with non-small cell lung cancer after radiotherapy. Chin J Cancer 2010;29:325-9 (in Chinese).
13. Schild S-E, Mc Ginnis W-L, Graham D et al. Results of a Phase I trial of concurrent chemotherapy and escalating doses of radiation for unresectable non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2006;65:1106-11.
14. Kong F-M, Ritter T, Quint D-J et al. Consideration of dose limits for organs at risk of thoracic radiotherapy: Atlas for lung, proximal bronchial tree, esophagus, spinal cord, ribs, and brachial plexus. Int J Radiat Oncol Biol Phys 2011;81:1442-57.
15. Socinski M-A, Rosenman J-G, Schell M-J et al. Induction carboplatin/paclitaxel followed by concurrent carboplatin/paclitaxel and dose-escalating conformal thoracic radiation therapy in unresectable stage IIIA/B nonsmall cell lung carcinoma: A modified Phase I trial. Cancer 2000;89:534-42.
16. Wu K-L, Jiang G-L, Liao Y et al. Three-dimensional conformal radiation therapy for non-small-cell lung cancer: A phase I/II dose escalation clinical trial. Int J Radiat Oncol Biol Phys 2003;57:1336-44.
17. Eisenhauer E-A, Therasse P, Bogaerts J et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 2009;45: 228-47.
18. Fletcher GH. Clinical dose response curves of human malignant epithelial tumors. Br J Radiol 1973;46:151.
19. Onishi H, Shirato H, Nagata Y et al. Hypofractionated stereotactic radiotherapy (HypoFXSRT) for stage I non-small cell lung cancer: Updated results of 257 patients in a Japanese multi-institutional study. J Thorac Oncol 2007;2(7 SUPPL3): S94-100.
20. Bradley J, Graham M-V, Winter K et al. Toxicity and outcome results of RTOG 9311: A phase I-II dose escalation study using three-dimensional conformal radiation therapy in patients with inoperable nonYsmall cell lung carcinoma. Int J Radiat Oncol Biol Phys 2005;61:318-28.
21. Dong J-L, Zhong J, Fu J-Z et al. A phase I/II study of dose escalation in non-small cell lung cancer with threedimensional conformal radiotherapy. Pract J Cancer 2009; 24:294-8 (in Chinese).
22. Wang X-Z, Wang L-H, Lv J-M et al. Concurrent paclitaxel and/or carboplatin with radiotherapy for stage III non-small cell lung cancer. Chin J Radiat Oncol 2006;15:270-4 (in Chinese).
23. Liu J, Lv C-X, Wang J-M et al. Analysis of two different concomitant radiochemotherapy regimens in the treatment of locally advanced stage III non-small cell lung cancer. Chin J Clin Oncol 2010;15:226-9 (in Chinese).
24. Wang J-P, Zhai X-M, Zhang J-N et al. Clinical study on concomitant radiotherapy in combination with vinorelbine and cisplatin for advanced non-small cell lung cancer. Acta Medicine of Jiangsu University 2005;16:483-5 (in Chinese).